• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Schechter Adam H was granted 348 shares, increasing direct ownership by 9% to 4,330 units (SEC Form 4)

    5/16/25 9:13:54 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Schechter Adam H

    (Last) (First) (Middle)
    C/O DAVITA INC.
    2000 16TH STREET

    (Street)
    DENVER CO 80202

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    DAVITA INC. [ DVA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/15/2025 A 348 A $0 4,330 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Stephanie N. Berberich, Attorney-in-Fact 05/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Inc. 2nd Quarter 2025 Results

    DENVER, Aug. 5, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another solid quarter, fueled by our unwavering focus on patient care," said Javier Rodriguez, CEO of DaVita Inc. "We continued to deliver exceptional clinical outcomes for our patients, fostered a positive experience for our caregivers, and delivered on our financial commitments with disciplined execution across our businesses." Financial and operating highlights for the quarter ended June 30, 2025: Consolidated revenues were $3.380 billion.Operating income was $538 million and adjusted operating income was $551 million.Diluted earnings

    8/5/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

    DENVER, July 17, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 5, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Tuesday, August 5, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t

    7/17/25 5:37:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates

    DENVER, May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita. "As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices (KCC) Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emph

    5/30/25 2:35:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schechter Adam H was granted 369 shares, increasing direct ownership by 9% to 4,699 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    8/19/25 5:25:32 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Yale Phyllis R was granted 369 shares, increasing direct ownership by 3% to 13,570 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    8/19/25 5:24:37 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Desoer Barbara J was granted 369 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    8/19/25 5:23:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

    11/1/22 9:18:39 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    SEC Filings

    View All

    SEC Form 10-Q filed by DaVita Inc.

    10-Q - DAVITA INC. (0000927066) (Filer)

    8/5/25 5:03:37 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    8/5/25 4:07:44 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - DAVITA INC. (0000927066) (Filer)

    7/17/25 4:01:26 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. 2nd Quarter 2025 Results

    DENVER, Aug. 5, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another solid quarter, fueled by our unwavering focus on patient care," said Javier Rodriguez, CEO of DaVita Inc. "We continued to deliver exceptional clinical outcomes for our patients, fostered a positive experience for our caregivers, and delivered on our financial commitments with disciplined execution across our businesses." Financial and operating highlights for the quarter ended June 30, 2025: Consolidated revenues were $3.380 billion.Operating income was $538 million and adjusted operating income was $551 million.Diluted earnings

    8/5/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

    DENVER, July 17, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 5, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Tuesday, August 5, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t

    7/17/25 5:37:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 1st Quarter 2025 Results

    DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: Consolidated revenues were $3.224 billion.Operating income was $439 million.Diluted earnings per share was $2.00.Operating cash flow was $180 million and free cash flow was $(45) million.Repurchased 3.7 milli

    5/12/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care